methylphenidate has been researched along with Cafe-au-Lait Spots with Pulmonic Stenosis in 7 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with methylphenidate (MPD) has improved learning disabilities in ADHD by acting on neurotransmitters." | 2.79 | The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial. ( Bréant, V; Combemale, P; Coutinho, V; des Portes, V; Gérard, D; Ginhoux, T; Gueyffier, F; Herbillon, V; Kassaï, B; Kemlin, I; Lion-François, L; Mercier, C; Peyric, E; Pinson, S; Rodriguez, D, 2014) |
| "Forty-six of 93 children with neurofibromatosis type 1 (NF1) were found to satisfy the diagnostic criteria for attention-deficit-hyperactivity disorder (ADHD)." | 2.70 | Treatment of ADHD in neurofibromatosis type 1. ( Kluwe, L; Leark, RA; Mautner, VF; Thakker, SD, 2002) |
| "Using an Nf1 optic glioma (OPG) GEM model, we report novel defects in non-selective and selective attention without an accompanying hyperactivity phenotype." | 1.36 | Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. ( Brown, JA; Conyers, SB; Emnett, RJ; Gutmann, DH; O'Malley, KL; White, CR; Wozniak, DF; Yuede, CM, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pride, NA | 1 |
| Barton, B | 1 |
| Hutchins, P | 1 |
| Coghill, DR | 1 |
| Korgaonkar, MS | 1 |
| Hearps, SJC | 1 |
| Rouel, M | 1 |
| Malarbi, S | 1 |
| North, KN | 1 |
| Payne, JM | 1 |
| Lidzba, K | 1 |
| Granstroem, S | 1 |
| Leark, RA | 2 |
| Kraegeloh-Mann, I | 1 |
| Mautner, VF | 3 |
| Lion-François, L | 1 |
| Gueyffier, F | 1 |
| Mercier, C | 1 |
| Gérard, D | 1 |
| Herbillon, V | 1 |
| Kemlin, I | 1 |
| Rodriguez, D | 1 |
| Ginhoux, T | 1 |
| Peyric, E | 1 |
| Coutinho, V | 1 |
| Bréant, V | 1 |
| des Portes, V | 1 |
| Pinson, S | 1 |
| Combemale, P | 1 |
| Kassaï, B | 1 |
| Brown, JA | 2 |
| Emnett, RJ | 1 |
| White, CR | 1 |
| Yuede, CM | 1 |
| Conyers, SB | 1 |
| O'Malley, KL | 1 |
| Wozniak, DF | 2 |
| Gutmann, DH | 2 |
| Xu, J | 1 |
| Diggs-Andrews, KA | 1 |
| Mach, RH | 1 |
| Kluwe, L | 1 |
| Thakker, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comportemental and Neuropsychologic Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate. A Double-blind Randomised Study Methylphenidate Versus Placebo[NCT00169611] | Phase 4 | 80 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for methylphenidate and Cafe-au-Lait Spots with Pulmonic Stenosis
| Article | Year |
|---|---|
Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial.
Topics: Adolescent; Central Nervous System Stimulants; Child; Child Behavior; Clinical Protocols; Cognition; | 2018 |
The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial.
Topics: Child; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up | 2014 |
Treatment of ADHD in neurofibromatosis type 1.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Behavior; Central Nervous System Stimulant | 2002 |
4 other studies available for methylphenidate and Cafe-au-Lait Spots with Pulmonic Stenosis
| Article | Year |
|---|---|
Pharmacotherapy of attention deficit in neurofibromatosis type 1: effects on cognition.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Child; Cognition; Dopamine Uptake I | 2014 |
Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Child; Corpus Striatum; Do | 2010 |
PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Carbon Radioisotopes; Corpus Stri | 2011 |
[Stimulant drugs in neurofibromatosis type 1 and attention deficit disorder].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2002 |